Hematology-oncology, often shortened to “hem-onc,” is the medical specialty focused on diagnosing, treating, and preventing blood diseases and blood-related cancers. It combines two overlapping fields: hematology (the study of blood, bone marrow, and lymph nodes) and oncology (the study and treatment of cancer). Because so many cancers originate in blood-forming cells, these two disciplines merged into a single specialty practiced by doctors who complete at least two years of specialized fellowship training after an internal medicine residency.
What the Specialty Covers
Hematology-oncology spans a surprisingly wide range of conditions. On the cancer side, the major diseases are leukemia, lymphoma, and multiple myeloma, all cancers of blood-forming organs. On the non-cancer side, hematologist-oncologists treat blood clots, bleeding disorders like hemophilia, anemias including sickle cell disease and thalassemia, and conditions where the body produces too few platelets or white blood cells.
This combination makes sense because the diagnostic tools overlap heavily. A doctor investigating unexplained anemia and a doctor diagnosing leukemia both need to understand bone marrow function, blood cell development, and the genetic changes that can push normal cells toward disease. Many patients first see a hematologist-oncologist for what turns out to be a benign condition, while others arrive with a confirmed cancer diagnosis needing treatment.
The Three Major Blood Cancers
Leukemia, lymphoma, and multiple myeloma are all cancers of blood-forming cells, but they behave differently depending on where the abnormal cells accumulate. In leukemia, cancerous cells circulate through the blood and bone marrow. Leukemia can arise in two main groups of white blood cells: lymphocytes or myelocytes, which is why you’ll see terms like “acute lymphocytic leukemia” or “acute myeloid leukemia.” The five-year survival rate for acute myeloid leukemia, one of the more aggressive forms, is about 33% based on recent data from the National Cancer Institute.
In lymphoma, the abnormal lymphocytes tend to cluster together and form solid masses in lymph nodes and other lymphatic tissues rather than circulating freely. Lymphoma comes in dozens of subtypes, broadly split into Hodgkin and non-Hodgkin categories, each with different behavior and outlook.
Multiple myeloma is a cancer of the bone marrow involving a specific type of white blood cell that normally produces antibodies. These myeloma cells crowd out healthy blood cells and produce an abnormal protein that can damage the kidneys and bones.
How These Cancers Are Diagnosed
Diagnosis typically involves a combination of blood tests, bone marrow sampling, and imaging. A bone marrow biopsy, where a doctor extracts a small core of bone and marrow (usually from the back of the hip), remains the standard method for evaluating many blood cancers. Lab technicians stain the samples and examine them under a microscope, looking for abnormal cells.
A technique called flow cytometry has become essential for identifying exactly which type of blood cancer is present. It works by tagging cells with fluorescent markers that attach to specific proteins on the cell surface. By analyzing which markers light up, the lab can determine the precise identity of abnormal cells and distinguish, for example, follicular lymphoma from mantle cell lymphoma. Multi-color flow cytometry can detect even small numbers of cancer cells that might be missed by microscopic examination alone.
The current international standard for classifying blood cancers is the World Health Organization’s 5th edition classification of haematolymphoid tumors, published in 2024. It integrates traditional microscopic examination with molecular and genetic testing, reflecting how central DNA-level analysis has become to modern diagnosis.
Targeted Therapy and Precision Medicine
Blood cancers were among the first to benefit from precision medicine. The best-known example involves chronic myeloid leukemia (CML), which is driven by an abnormal gene called BCR-ABL, created when two chromosomes accidentally swap material. This gene produces a protein that forces white blood cells to multiply uncontrollably. Drugs called tyrosine kinase inhibitors block that protein directly. Imatinib was the first, approved in the early 2000s, and it transformed CML from a near-certain death sentence into a manageable chronic condition. Several newer versions now exist for patients who don’t respond to the original drug or who develop resistance.
This targeted approach has expanded across hematology-oncology. Rather than relying solely on chemotherapy, which kills rapidly dividing cells indiscriminately, doctors now match treatments to the specific genetic mutations driving each patient’s cancer.
CAR-T Cell Therapy
One of the most significant recent advances in hematology-oncology is CAR-T cell therapy. The process starts by collecting a patient’s own immune cells from their blood. In a lab, those cells are genetically reprogrammed to recognize a specific protein on the surface of cancer cells. The modified cells are then multiplied into the hundreds of millions and infused back into the patient, where they hunt down and destroy cancer cells with a precision that conventional chemotherapy cannot match.
Six CAR-T products are currently approved by the FDA for blood cancers that have resisted other treatments, covering acute lymphocytic leukemia, several types of non-Hodgkin lymphoma (including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma), and multiple myeloma. These therapies have produced responses in patients who had exhausted all other options, though they can cause serious side effects and are currently reserved for cancers that have relapsed or stopped responding to standard treatment.
Stem Cell Transplants
Stem cell transplantation remains a cornerstone of treatment for many blood cancers. There are two main types. An autologous transplant uses the patient’s own stem cells, collected and stored before high-dose chemotherapy destroys the bone marrow, then returned to rebuild the blood system. This approach is most common in lymphoma and myeloma. The risk is that the collected cells may contain trace amounts of cancer.
An allogeneic transplant uses stem cells from a matched donor, which eliminates the contamination risk and offers a bonus: the donor’s immune cells can recognize and attack any remaining cancer, a phenomenon called the graft-versus-malignancy effect. This type is used predominantly for leukemias and certain bone marrow failure syndromes. The tradeoff is a higher risk of complications, since the donor’s immune cells can also attack the patient’s healthy tissues.
Non-Cancer Blood Disorders
A significant portion of hematology-oncology practice involves conditions that have nothing to do with cancer. Sickle cell disease, where red blood cells become rigid and crescent-shaped, causes pain crises and organ damage. Hemophilia and other bleeding disorders involve missing or defective clotting factors, leading to excessive bleeding from minor injuries. Thrombocytopenia, a low platelet count, can cause easy bruising and dangerous bleeding. Deep vein thrombosis, blood clots forming in the legs, can become life-threatening if a clot travels to the lungs.
These conditions share the same organ system as blood cancers and require the same foundational expertise in blood cell biology, bone marrow function, and coagulation pathways. Many hematologist-oncologists treat both cancer and non-cancer conditions, though some choose to focus their practice on one side or the other.